Inhaled Nitric Oxide Delivery Systems Market by Technology (Cylinder Gas, Electronic Generator), Delivery Device Type (Integrated Systems, Standalone), Mode Of Delivery, Application, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Inhaled Nitric Oxide Delivery Systems Market was valued at USD 312.75 million in 2024 and is projected to grow to USD 341.41 million in 2025, with a CAGR of 10.42%, reaching USD 691.18 million by 2032.
Comprehensive overview of the current clinical, technological, and operational dynamics shaping adoption of inhaled nitric oxide delivery systems
Inhaled nitric oxide delivery systems occupy a critical intersection between respiratory critical care and precision gas delivery technology. Clinical demand is driven by acute hypoxemic conditions across neonatal and adult care, while technological innovation is reshaping how clinicians deliver therapy with improved safety, portability, and dosing precision. The confluence of regulatory scrutiny, device integration, and evolving care pathways has created a dynamic environment in which manufacturers, healthcare providers, and payers must continuously adapt.
As stakeholders evaluate therapeutic value and operational feasibility, the landscape is being influenced by shifting clinical guidelines, increasing emphasis on home-based care, and the emergence of electronic generators that challenge traditional cylinder-based logistics. These factors together underscore the need for strategic clarity about product development priorities, channel strategies, and clinical evidence generation to ensure that delivery systems meet both acute care demands and long-term adoption criteria.
Key transformative trends reshaping clinical practice, device integration, and supply chain strategies for inhaled nitric oxide delivery systems
Several transformative shifts are redefining competitive dynamics in the inhaled nitric oxide delivery ecosystem, touching clinical protocols, technology architectures, and commercial models. First, the migration from exclusive hospital use toward ambulatory and home-based applications is accelerating, driven by improvements in portable electronic generators and clinician willingness to manage chronic or subacute conditions outside intensive care settings. This trend is catalyzing interest from device makers to prioritize compact, user-friendly systems that enable outpatient administration and telehealth-supported monitoring.
Second, integration between delivery device and monitoring systems is gaining prominence as a differentiator. Closed-loop controls, automated dosing adjustments, and connectivity for remote oversight are emerging as expectations rather than optional features, influencing procurement decisions at institutional and home-care levels. Third, regulatory expectations around safety, traceability, and interoperability are tightening, which is encouraging manufacturers to invest in robust quality systems and post-market evidence generation. Finally, supply chain considerations-especially gas sourcing and distribution logistics-are prompting creative channel strategies, including direct hospital partnerships and new distributor agreements, to ensure continuity of care and minimize treatment interruptions.
Assessment of how 2025 United States tariff changes are influencing supply chain resilience, procurement choices, and device design priorities across the sector
The introduction of tariff adjustments in the United States in 2025 has introduced a complex set of operational and strategic implications for providers, manufacturers, and distributors involved in inhaled nitric oxide delivery systems. Tariff changes affect the landed cost of hardware components, cylinders, and specialized electronics, prompting supply chain reconfigurations to preserve margins and ensure consistent product availability. Manufacturers with vertically integrated supply chains are better positioned to absorb or mitigate cost impacts, while those relying on international component sourcing face immediate pressure to reassess supplier contracts and inventory policies.
Clinicians and procurement teams may experience downstream effects as institutions re-evaluate capital expenditure plans and prioritize devices that reduce recurring consumable costs or enable multipurpose use across care settings. In parallel, distributors and logistics partners are revising contractual terms and service models to accommodate increased freight and importation complexity. To respond, stakeholders are pursuing several mitigations: renegotiating supplier terms, nearshoring assembly or component production where feasible, redesigning devices to substitute affected components, and accelerating adoption of electronic generators that reduce dependence on imported cylinders. These adaptive strategies are essential to maintain continuity of care and ensure that tariff-induced cost pressures do not compromise patient access or clinical outcomes.
Deep segmentation insight revealing how distinct application, end-user, technology, device type, channel, and delivery mode dynamics demand targeted commercial and clinical strategies
Segmentation analysis reveals distinct clinical and commercial pathways that demand targeted approaches across applications, end users, technologies, delivery device types, distribution channels, and modes of delivery. Based on application, the market is studied across adult, neonatal, and pediatric populations, where adult applications further focus on hypoxemia in cardiac surgery and pulmonary hypertension and neonatal uses concentrate on hypoxemic respiratory failure and persistent pulmonary hypertension of the newborn; each sub-application carries different evidence requirements, dosing protocols, and device ergonomics. Based on end user, the market is studied across ambulatory care centers, clinics, home healthcare, and hospitals, and the operational needs and purchasing cycles vary markedly between acute inpatient purchasers and home-care coordinators.
Based on technology, the market is studied across cylinder gas and electronic generator solutions, with electronic generators further differentiated between fixed and portable formats; technological selection influences maintenance models, training needs, and regulatory dossiers. Based on delivery device type, the market is studied across integrated systems and standalone devices, with integrated solutions often commanding premium positioning due to simplified workflows, while standalone devices enable modular deployment. Based on distribution channel, the market is studied across direct sales, distributors, and online channels, each offering distinct margins, service obligations, and customer relationships. Finally, based on mode of delivery, the market is studied across continuous and intermittent administration approaches, which have implications for device uptime, monitoring, and patient selection. Together, these segmentation lenses demonstrate that success requires tailored clinical evidence, channel strategies, and product roadmaps that reflect the unique requirements of each segment rather than a single one-size-fits-all offering.
Regional market dynamics and regulatory nuances that influence adoption pathways and commercial models across Americas, EMEA, and Asia-Pacific
Regional dynamics play a pivotal role in shaping regulatory pathways, adoption timelines, and commercial strategies for inhaled nitric oxide delivery systems. Americas markets are characterized by concentrated centers of excellence, strong hospital-based adoption, and a progressive regulatory environment that supports novel device approvals alongside structured reimbursement pathways. Procurement in these markets often hinges on institutional value propositions, clinical evidence, and long-term service agreements, while home-care adoption is gaining traction as payers and providers seek to reduce inpatient utilization.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks vary significantly, and centralized procurement mechanisms in some countries contrast with fragmented systems in others. In these regions, distributors and local partners are essential to navigate reimbursement nuances and to deliver post-sale clinical support. Asia-Pacific includes a mix of high-adoption, high-regulation markets and rapidly developing healthcare systems with growing demand for portable technologies and cost-efficient delivery models. Local manufacturing and partnerships are increasingly important in Asia-Pacific to meet price sensitivity and regulatory localization requirements. These regional differences underline the need for differentiated market entry tactics, adaptable service models, and targeted evidence generation to align with regional clinical practices and policy environments.
Competitive dynamics and strategic positioning that differentiate manufacturers through connectivity, service integration, and flexible manufacturing approaches
The competitive landscape for inhaled nitric oxide delivery systems is evolving as legacy device manufacturers, innovative medtech entrants, and specialty gas suppliers reposition around differentiated value propositions. Leading companies are prioritizing investments in device connectivity, remote monitoring capabilities, and integrated service offerings to create stickier relationships with hospitals and home-care providers. At the same time, new entrants are leveraging modular designs and software-driven dosing controls to challenge incumbents on usability and total cost of ownership.
Strategic activity also includes partnerships that combine clinical expertise with distribution reach, enabling faster adoption curves in varied care settings. Manufacturers are increasingly focused on building robust post-market evidence programs to demonstrate real-world performance, safety, and ease of use across diverse patient populations. Additionally, investments in manufacturing flexibility-such as the ability to switch between cylinder and generator supply chains-are helping firms manage supply disruptions and regulatory variability. Overall, competitive advantage is converging on the capacity to deliver comprehensive clinical support, rapid service response, and interoperable technologies that integrate into broader hospital and home-care ecosystems.
Actionable strategic priorities for manufacturers and providers to enhance product adoption, supply resilience, and clinical outcomes across diverse care settings
Industry leaders should pursue a set of pragmatic actions to convert current trends into sustainable advantages. First, invest in product architectures that balance portability with clinical-grade performance, enabling deployment across hospitals, ambulatory centers, and home-care programs while meeting clinician expectations for safety and monitoring. Second, prioritize interoperability and data integration to enable remote oversight, closed-loop control, and seamless incorporation into electronic health records and telehealth platforms, thereby improving clinician trust and easing adoption barriers.
Third, diversify supply chains and consider nearshoring or multi-sourcing strategies to reduce exposure to tariff volatility and logistical disruptions. Fourth, develop differentiated evidence generation plans tailored to each application and end-user segment, with an emphasis on real-world outcomes and health-economic analyses that resonate with payers and procurement teams. Fifth, refine channel strategies to combine direct engagements for large institutional customers with distributor and online options for wider geographic reach and faster deployment. These actions, taken together, will position organizations to capture evolving clinical demand while mitigating regulatory and supply-side risks.
Transparent multi-method research approach combining clinical evidence review, stakeholder interviews, regulatory analysis, and supply chain evaluation to support conclusions
This research synthesis is grounded in a multi-method approach that combines systematic literature review, regulatory dossier analysis, and expert stakeholder interviews to triangulate insights. Peer-reviewed clinical studies, device approvals, and guidance documents formed the evidence base for clinical pathway analysis, while technical white papers and product briefs informed the evaluation of device architectures and technological trade-offs. Interviews with clinicians, procurement officers, distributors, and device engineers provided practical perspectives on usability, service needs, and procurement dynamics.
To assess commercial and operational considerations, the methodology incorporated structured supplier mapping, review of public tender records where available, and analysis of tariff and trade policy documents to understand 2025 implications. Quality assurance steps included cross-validation of claims against multiple primary sources and a critical appraisal of data provenance. Where evidence gaps existed, the analysis used scenario-based reasoning and sensitivity testing to outline plausible strategic responses without relying on proprietary market sizing or forecasts.
Strategic conclusion emphasizing the need for aligned product design, evidence programs, and resilient supply chains to realize long-term adoption
Inhaled nitric oxide delivery systems stand at an inflection point where clinical need, technological capability, and supply chain realities converge to create both risk and opportunity. The push toward portable electronic generators and integrated delivery-monitoring systems is expanding the settings in which therapy can be delivered, while tariff shifts and regulatory evolution are accelerating strategic reassessments of sourcing and commercialization models. Stakeholders that align product design, evidence generation, and channel strategies with specific segment demands will be best positioned to capture long-term clinical trust and commercial sustainability.
Ultimately, the most successful organizations will be those that combine clinical rigor with operational agility-investing in technologies that reduce barriers to safe administration, forging partnerships that accelerate market access, and building resilient supply chains capable of adapting to geopolitical and policy-driven changes. This holistic orientation will ensure that therapeutic benefits reach the intended patient groups while supporting economically viable deployment across acute and non-acute care environments.
Note: PDF & Excel + Online Access - 1 Year
Comprehensive overview of the current clinical, technological, and operational dynamics shaping adoption of inhaled nitric oxide delivery systems
Inhaled nitric oxide delivery systems occupy a critical intersection between respiratory critical care and precision gas delivery technology. Clinical demand is driven by acute hypoxemic conditions across neonatal and adult care, while technological innovation is reshaping how clinicians deliver therapy with improved safety, portability, and dosing precision. The confluence of regulatory scrutiny, device integration, and evolving care pathways has created a dynamic environment in which manufacturers, healthcare providers, and payers must continuously adapt.
As stakeholders evaluate therapeutic value and operational feasibility, the landscape is being influenced by shifting clinical guidelines, increasing emphasis on home-based care, and the emergence of electronic generators that challenge traditional cylinder-based logistics. These factors together underscore the need for strategic clarity about product development priorities, channel strategies, and clinical evidence generation to ensure that delivery systems meet both acute care demands and long-term adoption criteria.
Key transformative trends reshaping clinical practice, device integration, and supply chain strategies for inhaled nitric oxide delivery systems
Several transformative shifts are redefining competitive dynamics in the inhaled nitric oxide delivery ecosystem, touching clinical protocols, technology architectures, and commercial models. First, the migration from exclusive hospital use toward ambulatory and home-based applications is accelerating, driven by improvements in portable electronic generators and clinician willingness to manage chronic or subacute conditions outside intensive care settings. This trend is catalyzing interest from device makers to prioritize compact, user-friendly systems that enable outpatient administration and telehealth-supported monitoring.
Second, integration between delivery device and monitoring systems is gaining prominence as a differentiator. Closed-loop controls, automated dosing adjustments, and connectivity for remote oversight are emerging as expectations rather than optional features, influencing procurement decisions at institutional and home-care levels. Third, regulatory expectations around safety, traceability, and interoperability are tightening, which is encouraging manufacturers to invest in robust quality systems and post-market evidence generation. Finally, supply chain considerations-especially gas sourcing and distribution logistics-are prompting creative channel strategies, including direct hospital partnerships and new distributor agreements, to ensure continuity of care and minimize treatment interruptions.
Assessment of how 2025 United States tariff changes are influencing supply chain resilience, procurement choices, and device design priorities across the sector
The introduction of tariff adjustments in the United States in 2025 has introduced a complex set of operational and strategic implications for providers, manufacturers, and distributors involved in inhaled nitric oxide delivery systems. Tariff changes affect the landed cost of hardware components, cylinders, and specialized electronics, prompting supply chain reconfigurations to preserve margins and ensure consistent product availability. Manufacturers with vertically integrated supply chains are better positioned to absorb or mitigate cost impacts, while those relying on international component sourcing face immediate pressure to reassess supplier contracts and inventory policies.
Clinicians and procurement teams may experience downstream effects as institutions re-evaluate capital expenditure plans and prioritize devices that reduce recurring consumable costs or enable multipurpose use across care settings. In parallel, distributors and logistics partners are revising contractual terms and service models to accommodate increased freight and importation complexity. To respond, stakeholders are pursuing several mitigations: renegotiating supplier terms, nearshoring assembly or component production where feasible, redesigning devices to substitute affected components, and accelerating adoption of electronic generators that reduce dependence on imported cylinders. These adaptive strategies are essential to maintain continuity of care and ensure that tariff-induced cost pressures do not compromise patient access or clinical outcomes.
Deep segmentation insight revealing how distinct application, end-user, technology, device type, channel, and delivery mode dynamics demand targeted commercial and clinical strategies
Segmentation analysis reveals distinct clinical and commercial pathways that demand targeted approaches across applications, end users, technologies, delivery device types, distribution channels, and modes of delivery. Based on application, the market is studied across adult, neonatal, and pediatric populations, where adult applications further focus on hypoxemia in cardiac surgery and pulmonary hypertension and neonatal uses concentrate on hypoxemic respiratory failure and persistent pulmonary hypertension of the newborn; each sub-application carries different evidence requirements, dosing protocols, and device ergonomics. Based on end user, the market is studied across ambulatory care centers, clinics, home healthcare, and hospitals, and the operational needs and purchasing cycles vary markedly between acute inpatient purchasers and home-care coordinators.
Based on technology, the market is studied across cylinder gas and electronic generator solutions, with electronic generators further differentiated between fixed and portable formats; technological selection influences maintenance models, training needs, and regulatory dossiers. Based on delivery device type, the market is studied across integrated systems and standalone devices, with integrated solutions often commanding premium positioning due to simplified workflows, while standalone devices enable modular deployment. Based on distribution channel, the market is studied across direct sales, distributors, and online channels, each offering distinct margins, service obligations, and customer relationships. Finally, based on mode of delivery, the market is studied across continuous and intermittent administration approaches, which have implications for device uptime, monitoring, and patient selection. Together, these segmentation lenses demonstrate that success requires tailored clinical evidence, channel strategies, and product roadmaps that reflect the unique requirements of each segment rather than a single one-size-fits-all offering.
Regional market dynamics and regulatory nuances that influence adoption pathways and commercial models across Americas, EMEA, and Asia-Pacific
Regional dynamics play a pivotal role in shaping regulatory pathways, adoption timelines, and commercial strategies for inhaled nitric oxide delivery systems. Americas markets are characterized by concentrated centers of excellence, strong hospital-based adoption, and a progressive regulatory environment that supports novel device approvals alongside structured reimbursement pathways. Procurement in these markets often hinges on institutional value propositions, clinical evidence, and long-term service agreements, while home-care adoption is gaining traction as payers and providers seek to reduce inpatient utilization.
Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks vary significantly, and centralized procurement mechanisms in some countries contrast with fragmented systems in others. In these regions, distributors and local partners are essential to navigate reimbursement nuances and to deliver post-sale clinical support. Asia-Pacific includes a mix of high-adoption, high-regulation markets and rapidly developing healthcare systems with growing demand for portable technologies and cost-efficient delivery models. Local manufacturing and partnerships are increasingly important in Asia-Pacific to meet price sensitivity and regulatory localization requirements. These regional differences underline the need for differentiated market entry tactics, adaptable service models, and targeted evidence generation to align with regional clinical practices and policy environments.
Competitive dynamics and strategic positioning that differentiate manufacturers through connectivity, service integration, and flexible manufacturing approaches
The competitive landscape for inhaled nitric oxide delivery systems is evolving as legacy device manufacturers, innovative medtech entrants, and specialty gas suppliers reposition around differentiated value propositions. Leading companies are prioritizing investments in device connectivity, remote monitoring capabilities, and integrated service offerings to create stickier relationships with hospitals and home-care providers. At the same time, new entrants are leveraging modular designs and software-driven dosing controls to challenge incumbents on usability and total cost of ownership.
Strategic activity also includes partnerships that combine clinical expertise with distribution reach, enabling faster adoption curves in varied care settings. Manufacturers are increasingly focused on building robust post-market evidence programs to demonstrate real-world performance, safety, and ease of use across diverse patient populations. Additionally, investments in manufacturing flexibility-such as the ability to switch between cylinder and generator supply chains-are helping firms manage supply disruptions and regulatory variability. Overall, competitive advantage is converging on the capacity to deliver comprehensive clinical support, rapid service response, and interoperable technologies that integrate into broader hospital and home-care ecosystems.
Actionable strategic priorities for manufacturers and providers to enhance product adoption, supply resilience, and clinical outcomes across diverse care settings
Industry leaders should pursue a set of pragmatic actions to convert current trends into sustainable advantages. First, invest in product architectures that balance portability with clinical-grade performance, enabling deployment across hospitals, ambulatory centers, and home-care programs while meeting clinician expectations for safety and monitoring. Second, prioritize interoperability and data integration to enable remote oversight, closed-loop control, and seamless incorporation into electronic health records and telehealth platforms, thereby improving clinician trust and easing adoption barriers.
Third, diversify supply chains and consider nearshoring or multi-sourcing strategies to reduce exposure to tariff volatility and logistical disruptions. Fourth, develop differentiated evidence generation plans tailored to each application and end-user segment, with an emphasis on real-world outcomes and health-economic analyses that resonate with payers and procurement teams. Fifth, refine channel strategies to combine direct engagements for large institutional customers with distributor and online options for wider geographic reach and faster deployment. These actions, taken together, will position organizations to capture evolving clinical demand while mitigating regulatory and supply-side risks.
Transparent multi-method research approach combining clinical evidence review, stakeholder interviews, regulatory analysis, and supply chain evaluation to support conclusions
This research synthesis is grounded in a multi-method approach that combines systematic literature review, regulatory dossier analysis, and expert stakeholder interviews to triangulate insights. Peer-reviewed clinical studies, device approvals, and guidance documents formed the evidence base for clinical pathway analysis, while technical white papers and product briefs informed the evaluation of device architectures and technological trade-offs. Interviews with clinicians, procurement officers, distributors, and device engineers provided practical perspectives on usability, service needs, and procurement dynamics.
To assess commercial and operational considerations, the methodology incorporated structured supplier mapping, review of public tender records where available, and analysis of tariff and trade policy documents to understand 2025 implications. Quality assurance steps included cross-validation of claims against multiple primary sources and a critical appraisal of data provenance. Where evidence gaps existed, the analysis used scenario-based reasoning and sensitivity testing to outline plausible strategic responses without relying on proprietary market sizing or forecasts.
Strategic conclusion emphasizing the need for aligned product design, evidence programs, and resilient supply chains to realize long-term adoption
Inhaled nitric oxide delivery systems stand at an inflection point where clinical need, technological capability, and supply chain realities converge to create both risk and opportunity. The push toward portable electronic generators and integrated delivery-monitoring systems is expanding the settings in which therapy can be delivered, while tariff shifts and regulatory evolution are accelerating strategic reassessments of sourcing and commercialization models. Stakeholders that align product design, evidence generation, and channel strategies with specific segment demands will be best positioned to capture long-term clinical trust and commercial sustainability.
Ultimately, the most successful organizations will be those that combine clinical rigor with operational agility-investing in technologies that reduce barriers to safe administration, forging partnerships that accelerate market access, and building resilient supply chains capable of adapting to geopolitical and policy-driven changes. This holistic orientation will ensure that therapeutic benefits reach the intended patient groups while supporting economically viable deployment across acute and non-acute care environments.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of portable and wearable inhaled nitric oxide delivery devices for neonatal and adult critical care
- 5.2. Integration of AI-driven dosing algorithms to optimize inhaled nitric oxide delivery and clinical outcomes
- 5.3. Expansion of inhaled nitric oxide therapy into adult pulmonary hypertension treatment beyond neonatal care
- 5.4. Advances in sensor technology enabling real-time monitoring of inhaled nitric oxide and methemoglobin levels
- 5.5. Rising demand for home-based inhaled nitric oxide therapy following early hospital discharge protocols
- 5.6. Collaboration between medical device manufacturers and pharmaceutical firms for combination nitric oxide therapies
- 5.7. Regulatory approvals and expedited review pathways for next-generation inhaled nitric oxide systems in emerging markets
- 5.8. Development of eco-friendly nitric oxide generation technologies reducing reliance on chemical gas cylinders
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Inhaled Nitric Oxide Delivery Systems Market, by Technology
- 8.1. Cylinder Gas
- 8.2. Electronic Generator
- 8.2.1. Fixed
- 8.2.2. Portable
- 9. Inhaled Nitric Oxide Delivery Systems Market, by Delivery Device Type
- 9.1. Integrated Systems
- 9.2. Standalone
- 10. Inhaled Nitric Oxide Delivery Systems Market, by Mode Of Delivery
- 10.1. Continuous
- 10.2. Intermittent
- 11. Inhaled Nitric Oxide Delivery Systems Market, by Application
- 11.1. Adult
- 11.1.1. Hypoxemia In Cardiac Surgery
- 11.1.2. Pulmonary Hypertension
- 11.2. Neonatal
- 11.2.1. Hypoxemic Respiratory Failure
- 11.2.2. Persistent Pulmonary Hypertension Of The Newborn
- 11.3. Pediatric
- 12. Inhaled Nitric Oxide Delivery Systems Market, by End User
- 12.1. Ambulatory Care Centers
- 12.2. Clinics
- 12.3. Home Healthcare
- 12.4. Hospitals
- 13. Inhaled Nitric Oxide Delivery Systems Market, by Distribution Channel
- 13.1. Direct Sales
- 13.2. Distributors
- 13.3. Online Channels
- 14. Inhaled Nitric Oxide Delivery Systems Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Inhaled Nitric Oxide Delivery Systems Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Inhaled Nitric Oxide Delivery Systems Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Air Liquide S.A.
- 17.3.2. Air Products and Chemicals, Inc.
- 17.3.3. Air Water Inc.
- 17.3.4. Bellerophon Therapeutics, Inc.
- 17.3.5. Beyond Air, Inc.
- 17.3.6. Chart Industries, Inc.
- 17.3.7. Drägerwerk AG & Co. KGaA
- 17.3.8. EKU Elektronik GmbH
- 17.3.9. GE HealthCare Technologies Inc.
- 17.3.10. Getinge AB
- 17.3.11. INO Therapeutics LLC
- 17.3.12. International Biomedical Ltd.
- 17.3.13. Koninklijke Philips N.V.
- 17.3.14. Linde plc
- 17.3.15. Mallinckrodt Pharmaceuticals plc
- 17.3.16. Medtronic plc
- 17.3.17. Merck KGaA
- 17.3.18. Messer Group GmbH
- 17.3.19. NIOX Group plc
- 17.3.20. Novoteris, LLC
- 17.3.21. NU-MED Plus, Inc.
- 17.3.22. SLE Ltd.
- 17.3.23. Taiyo Nippon Sanso Corporation
- 17.3.24. Teleflex Incorporated
- 17.3.25. VERO Biotech LLC
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
